SOP Templates

Corrective Action and Preventive Action (CAPA) is a critical component of the Quality Management System (QMS) and is essential for ensuring compliance with regulatory requirements such as current Good Manufacturing Practices (cGMP), as well as maintaining safety, efficacy, and quality of pharmaceutical products. The CAPA process aims to address both the root causes of identified non-conformances and deviations and to implement measures that prevent recurrence.

Deviation management is a critical component of the Quality Management System (QMS) and supports compliance with current Good Manufacturing Practices (cGMP) as outlined by regulatory authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.

This Standard Operating Procedure (SOP) template defines the process for identifying, documenting, investigating, and addressing EM excursions within pharmaceutical manufacturing and cleanroom environments. An EM excursion refers to any result that falls outside of established microbiological or physical control limits, potentially impacting product quality or aseptic conditions. This SOP helps the user to ensure that all such deviations are handled in a timely manner, in accordance with applicable regulatory guidelines such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and European Union (EU) Good Manufacturing Practice (GMP) Annex 1 through timely investigation, risk assessment, and resolution while linking directly to the corrective action and preventive action (CAPA) system to facilitate root cause analysis, implementation of corrective measures, and monitoring of recurrence trends.

This Standard Operating Procedure (SOP) includes a template to help the user outline the systematic approach to conducting investigations related to deviations, non-conformances, Out-of-Specification (OOS) results, product complaints, and other quality-related events within a pharmaceutical company’s operations.

This Standard Operating Procedure (SOP) template provides a structured approach for the identification, investigation, evaluation, and resolution of Out-of-Specification (OOS) results observed during pharmaceutical manufacturing and testing. The objective is to ensure that all OOS results, whether from in-process testing, finished product testing, raw materials, or in-process samples, are addressed in a scientifically sound, compliant, and timely manner while upholding regulatory requirements and promoting product quality and patient safety.

This Standard Operating Procedure (SOP) includes a template that helps the user outline the process for receiving, documenting, evaluating, and resolving product quality complaints within the pharmaceutical organization. The purpose of the SOP is to ensure that all reported product quality issues are managed in a consistent, timely, and compliant manner in alignment with applicable regulatory requirements, such as the US Food and Drug Administration (FDA) 21 CFR, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.

This SOP includes a template that helps the user to establish a clear and systematic process for the initiation, coordination, and execution of product recalls within the pharmaceutical organization. The purpose of this SOP is to ensure that any product deemed potentially harmful, defective, or noncompliant with regulatory requirements is promptly and effectively removed from the market.